Last updated on October 2014

A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza


Brief description of study

A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza

Detailed Study Description

This 2-arm study will investigate the safety and tolerability of twice daily con ventional and double dose Tamiflu (oseltamivir) for the treatment of influenza i n immunocompromised patients. Eligible immunocompromised patients with laborator y-confirmed influenza will be randomized to receive either conventional dose (30 mg-75mg twice daily po, depending on age and weight) or double dose (60mg-150mg twice daily po depending on age and weight) Tamiflu for 10 days. Nasal and throa t swabs will be taken, and safety evaluations made, at intervals during the stud y. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.

Clinical Study Identifier: TX139364

Find a site near you

Start Over
Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.